source
- STAT+: Breast cancer pill from AstraZeneca misses mark in pivotal trialA pill from AstraZeneca failed to improve outcomes in closely watched breast cancer study, a result that could limit the use of the medicine.STAT · 9m ago↗ source
- FDA approves Isembyld, first therapy to target muscle loss in SMA patientsScholar Rock received FDA approval for Isembyld, the first drug designed to address muscle loss in spinal muscular atrophy (SMA). The approval covers adults and children aged two years and older w…